Napsin B (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Human Napsin B (NAPSA, UniProt O96009) recombinant protein expressed in HEK293 cells. Suitable for aspartyl protease activity assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-NapsinB

In stock

SKU
REC-NapsinB
$498.00

Target Overview

Napsin B (also catalogued under the NAPSA gene) is a member of the aspartyl protease family, sharing structural and functional characteristics with the closely related Napsin-A (UniProt O96009). The full-length human protein spans 420 amino acids and is characterised by the conserved bilobal aspartyl protease fold carrying two catalytic aspartate residues. Napsin proteins are synthesised as zymogens and require proteolytic processing to reach their mature, active forms. This recombinant is produced in HEK293 mammalian cells, a system that supports the glycosylation patterns and disulfide-bond formation expected of a secreted aspartyl protease, making it more representative of the native protein than equivalent bacterial or insect-cell preparations. The secreted nature of the protein (consistent with UniProt annotation) means that post-translational modifications relevant to its function are preserved. Researchers use this recombinant in several experimental contexts. In enzymatic activity assays, it serves as the active enzyme source against defined peptide or protein substrates, allowing kinetic parameter (Km, Vmax, kcat) determination. In inhibitor-profiling workflows, it is used to generate IC50 data for candidate small-molecule aspartyl protease inhibitors. As a positive control antigen, it provides a defined, soluble protein for Western blot, ELISA, and IHC antibody validation experiments — researchers working with Triple Point Biologics' matched antibody (SKU: RP-NapsinB) can pair the two reagents directly to confirm band specificity and signal linearity. The recombinant is also suitable as a calibration standard in immunoassay development and as a substrate-engagement model for surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding studies.

Background

Napsin-A/B, encoded by the NAPSA gene, belongs to the pepsin-like aspartyl protease superfamily. Canonical aspartyl proteases in this family cleave peptide bonds via two catalytic aspartate residues situated within a deep, hydrophobic active-site cleft. Napsin-A is expressed predominantly in the lung and kidney, with particularly high expression in type II alveolar pneumocytes, where it has been investigated as a participant in the proteolytic processing of pulmonary surfactant protein precursors — a process critical to normal alveolar surface-tension homeostasis. In research, Napsin-A has become one of the most widely studied immunohistochemical markers for lung adenocarcinoma. Its restricted tissue expression pattern makes it useful in panels designed to determine the origin of metastatic or morphologically ambiguous adenocarcinomas. A 2026 histopathology study (Toussieng et al., Histopathology, PMID 41521654) examined the expression of pulmonary immunohistochemical markers including Napsin-A in gastric adenocarcinomas associated with autoimmune metaplastic atrophic gastritis, illustrating how understanding Napsin-A expression boundaries informs diagnostic panel design in surgical pathology research. Beyond its diagnostic utility, Napsin-A has been characterised as a tumour-associated antigen capable of eliciting adaptive immune responses. Miller et al. (J Immunother Cancer, 2025, PMID 40664448) reported that Napsin A-specific T-cell clonotypes were associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer — positioning Napsin-A as a research target for tumour immunology studies focused on antigen-specific T-cell responses. More recently, multiomics approaches have used Napsin-A expression as part of molecular classification schemes for lung adenocarcinoma subtypes (Nacer et al., Genome Med, 2026, PMID 41691315), and targeted biomarker panels have evaluated Napsin-A alongside other markers such as CDC20 for malignant pleural effusion classification (Liu et al., Sci Rep, 2026, PMID 41775889). These published applications illustrate the breadth of contexts — from basic protease biology to tumour immunology and clinical biomarker research — in which well-characterised recombinant Napsin protein is a useful reagent. Triple Point Biologics has supplied proteinase and inhibitor antibody reagents since 1994, and this recombinant is produced to complement that antibody portfolio for researchers requiring a defined protein standard.

Applications

  • Aspartyl protease kinetic activity assay (Km, Vmax, kcat determination against peptide substrates)
  • Small-molecule inhibitor IC50 profiling in fluorescence-based cleavage assays
  • Western blot positive control antigen for antibody validation (pairs with TPB antibody SKU: RP-NapsinB)
  • IHC staining protocol optimisation and antibody titration standard
  • ELISA calibration standard and capture-antigen coating for immunoassay development
  • Biolayer interferometry (BLI) or surface plasmon resonance (SPR) binding studies with candidate inhibitors or binding partners
  • Substrate specificity profiling by mass spectrometry-based peptide cleavage analysis
  • Tumour-antigen preparation for in vitro T-cell stimulation assays in lung adenocarcinoma immunology research

References

  1. Liu Y et al. The diagnostic value of CDC20 for malignant pleural effusion of lung adenocarcinoma. Sci Rep. 2026. doi:10.1038/s41598-026-41506-2. PMID: 41775889.
  2. Nacer DF et al. Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation. Genome Med. 2026. doi:10.1186/s13073-026-01609-x. PMID: 41691315.
  3. Toussieng T et al. Pulmonary immunohistochemical markers may be positive in gastric adenocarcinomas associated with autoimmune metaplastic atrophic gastritis. Histopathology. 2026. doi:10.1111/his.15526. PMID: 41521654.
  4. Miller NJ et al. Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer. J Immunother Cancer. 2025. doi:10.1136/jitc-2025-011907. PMID: 40664448.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosomal; kidney + lung

Frequently Asked Questions

What molecular weight should I expect for recombinant Napsin B on SDS-PAGE or Western blot?

The full-length human Napsin B precursor is 420 amino acids, giving a predicted MW of ~46 kDa. However, HEK293-expressed material carries N-linked glycosylation consistent with the native secreted form, so the apparent MW on reducing SDS-PAGE typically runs at 50–55 kDa. Under non-reducing conditions, intramolecular disulfide bonds can cause slight mobility shifts. If you are running a Western blot positive control alongside RP-NapsinB antibody, expect your band in the 50–55 kDa window rather than at the theoretical unmodified mass.

Is this recombinant Napsin B the zymogen form or the mature processed form? Does it need activation?

Napsin B is synthesised naturally as a zymogen requiring proteolytic removal of its propeptide to reach the catalytically active form. The Triple Point Biologics REC-NapsinB is supplied as the active, processed enzyme — propeptide cleavage has been carried out during production in HEK293 cells, mirroring the maturation that occurs in the secretory pathway. No additional activation step is required before use in enzymatic assays. If your experiment specifically requires the zymogen form, contact us before ordering, as this preparation is not the precursor.

What substrates does recombinant Napsin B cleave and what activity assay should I use?

As a member of the aspartyl protease family, Napsin B cleaves substrates at low pH using two catalytic aspartate residues. Fluorogenic peptide substrates designed for aspartyl proteases — such as those based on the cleavage motif recognized by cathepsin D or pepsin — are a practical starting point. Activity is typically measured in 100 mM sodium acetate, pH 3.5–4.5, using a substrate concentration near Km (commonly 10–50 µM). Confirm activity is abolished by pepstatin A (a pan-aspartyl protease inhibitor) as a specificity control. Reported enzyme concentrations for kinetic assays typically begin at 5–50 nM.

What buffer is recombinant Napsin B supplied in and what are the optimal assay buffer conditions?

REC-NapsinB is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — a storage buffer chosen to maintain stability, not optimised for catalysis. For enzymatic assays, transfer the enzyme into an acidic activity buffer: 100 mM sodium acetate or citrate-phosphate buffer at pH 3.5–4.5, where aspartyl proteases are active. Keep glycerol ≤1% in the assay to avoid fluorescence interference. Add BSA (0.01–0.1%) as a carrier if working at sub-nanomolar enzyme concentrations to reduce non-specific adsorption to tube walls.

What starting concentration of recombinant Napsin B should I use for IC50 inhibitor screening?

For IC50 determinations, begin with an enzyme concentration of 5–20 nM in assay buffer (pH 3.5–4.5) and titrate inhibitor across at least 8–10 concentrations spanning 3 logs. Working near or below the enzyme Km for your fluorogenic substrate gives the most accurate apparent Ki. Pre-incubate enzyme with inhibitor for 15–30 minutes at 37°C before initiating the reaction with substrate, particularly for slow-binding inhibitors. Pepstatin A at 1 µM serves as a full inhibition positive control. Confirm DMSO tolerance up to 1% v/v, as higher concentrations can destabilise aspartyl protease activity.

Can I use REC-NapsinB as a positive control for Western blot with the RP-NapsinB polyclonal antibody?

Yes — REC-NapsinB and RP-NapsinB are matched in-house at Triple Point Biologics and guaranteed compatible for this application. Load 50–100 ng of recombinant protein per lane on a standard 10–12% SDS-PAGE gel under reducing conditions. Expect a band at 50–55 kDa (reflecting glycosylation). The RP-NapsinB rabbit polyclonal is validated for Western blot and provides a clean positive control signal at this loading, useful both for antibody titration and for confirming endogenous Napsin B detection in cell or tissue lysates running at the same apparent MW.

How much recombinant Napsin B should I load to validate RP-NapsinB antibody performance in a new Western blot protocol?

For antibody validation, a two-point loading of 25 ng and 100 ng per lane allows you to confirm linearity of signal and establish the antibody's dynamic range. Run alongside a cell lysate known to express Napsin B (e.g., lung adenocarcinoma lines) to demonstrate concordance between recombinant and endogenous bands at ~50–55 kDa. Use RP-NapsinB at its recommended working dilution (refer to the RP-NapsinB datasheet at /anti-napsinb-rabbit-polyclonal-antibody). Including a no-primary negative control lane is essential to distinguish specific signal from background.

How should I store and handle recombinant Napsin B to preserve enzymatic activity long-term?

Store REC-NapsinB at -20°C in the single-use aliquots as supplied. The 10% glycerol in the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) acts as a cryoprotectant and prevents ice-crystal damage to the protein structure. Avoid repeated freeze-thaw cycles — each cycle can cause measurable activity loss for aspartyl proteases with disulfide-dependent tertiary structure. On the day of use, thaw on ice and dilute directly into pre-cooled assay buffer. Do not vortex; mix by gentle pipetting. Aliquots are stable for up to 12 months at -20°C when stored correctly.

Validation imagery coming soon

Western blot validation figures for REC-NapsinB will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →